|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Alabama at Birmingham |
|---|---|
| Collaborator: |
National Cancer Institute (NCI) |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00002734 |
Purpose
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon may interfere with the growth of cancer cells. Combining monoclonal antibody, chemotherapy, and interferon alfa may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody, paclitaxel, and interferon alfa in treating patients who have ovarian cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Ovarian Cancer Peritoneal Cavity Cancer |
Biological: recombinant interferon alfa Drug: chemotherapy Drug: paclitaxel Drug: topotecan hydrochloride Radiation: lutetium Lu 177 monoclonal antibody CC49 Radiation: yttrium Y 90 monoclonal antibody CC49 |
Phase I |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | PHASE I STUDY OF INTERFERON ENHANCED INTRAPERITONEAL RADIOIMMUNO-CHEMOTHERAPY FOR OVARIAN CANCER |
| Estimated Enrollment: | 30 |
| Study Start Date: | March 1996 |
OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of intraperitoneal paclitaxel and topotecan when administered as a radiosensitizer prior to intraperitoneal lutetium Lu 177 monoclonal antibody CC49 (177Lu-CC49) following subcutaneous interferon alfa-2b (IFN-A) in patients with persistent or recurrent ovarian cancer. II. Determine the toxicity associated with intraperitoneal paclitaxel and topotecan in these patients. III. Examine the conjugate stability, pharmacokinetics, and biodistribution of 177Lu-CC49 given 48 hours after intraperitoneal paclitaxel. IV. Determine the effects of IFN-A and intraperitoneal paclitaxel on 177Lu-CC49 tumor localization and dosimetry estimates compared to a prior trial with 177Lu-CC49 alone. V. Determine the MTD of yttrium Y 90 monoclonal antibody CC49 (90Y-CC49) when administered with IFN-A and the dose of paclitaxel used at the MTD level of IFN-A, paclitaxel, and 177Lu-CC49. VI. Monitor any antitumor effects of this treatment in these patients.
OUTLINE: This is a dose escalation study of paclitaxel, topotecan, lutetium LU 177 monoclonal antibody CC-49 (177Lu-CC49), and yttrium Y 90 monoclonal antibody CC49 (90Y-CC49). Patients receive interferon alfa subcutaneously on days 1, 3, 5, and 7; paclitaxel intraperitoneally (IP) on day 4 or topotecan IP on day 6; and 177Lu-CC49 IP on day 6. Treatment continues every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-5 patients receive escalating doses of paclitaxel and decreasing doses of 177Lu-CC49 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 5 patients experience dose limiting toxicity. Once the MTD of paclitaxel is determined, the dose of 177Lu-CC49 is escalated. Once the MTD of 177Lu-CC49 is determined, 90Y-CC49 is substituted. The MTD of 90Y-CC49 is then determined when administered with paclitaxel. Topotecan is then substituted for paclitaxel (administered with the MTD of 177Lu-CC49 and interferon alfa only) and escalated until the MTD is determined. Patients are followed at 6 weeks and then every 3 months for 1 year.
PROJECTED ACCRUAL: Approximately 22-30 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the ovary or papillary serous carcinoma of extraovarian origin Recurrent or persistent following standard surgery and 1 or 2 chemotherapy regimens (with or without paclitaxel), i.e.: Persistent disease or progression after chemotherapy with nodules less than the equivalent of 5 x 5 x 5 cm Recurrent carcinoma (after primary or secondary chemotherapy) detected clinically either by exam or rising CA 125 and with radiographic evidence of disease no greater than the equivalent of 5 x 5 x 5 cm nodules Residual disease less than 5 x 5 x 5 cm following reassessment laparotomy Microscopic residual disease on reassessment laparotomy after chemotherapy Tumor TAG-72 positive by immunoperoxidase staining of original or current tumor blocks At least 85% free flow of fluid in peritoneal cavity demonstrated by technetium-99m scan or other imaging within 2 weeks prior to treatment No evidence of disease outside the peritoneal cavity other than retroperitoneal lymphadenopathy No massive ascites
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 125,000/mm3 Hemoglobin greater than 9 g/dL No nucleated RBC or significant teardrop RBC morphology Hepatic: Bilirubin less than 1.5 mg/dL AST/ALT less than 4 times normal Renal: Creatinine less than 2.0 mg/dL Other: HIV negative Hepatitis B surface antigen negative No hypersensitivity to paclitaxel, polyoxethylated castor oil, or topotecan No other malignancy in past 5 years except basal cell skin carcinoma Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy and recovered No prior monoclonal antibody therapy No concurrent immunotherapy No prior bone marrow or stem cell transplantation Chemotherapy: See Disease Characteristics At least 3 weeks since prior chemotherapy (6 weeks since nitrosoureas or mitomycin) and recovered No concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior radiotherapy and recovered No prior radiotherapy to the abdominal cavity No concurrent radiotherapy Surgery: See Disease Characteristics At least 3 weeks since prior major surgery and recovered Other: No prior intraperitoneal therapy
Contacts and Locations| United States, Alabama | |
| University of Alabama Comprehensive Cancer Center | |
| Birmingham, Alabama, United States, 35294 | |
| Study Chair: | Ruby F. Meredith, MD, PhD | University of Alabama at Birmingham |
More Information
| Study ID Numbers: | CDR0000064633, UAB-9502, NCI-B95-0003 |
| Study First Received: | November 1, 1999 |
| Last Updated: | May 30, 2009 |
| ClinicalTrials.gov Identifier: | NCT00002734 History of Changes |
| Health Authority: | United States: Federal Government |
|
recurrent ovarian epithelial cancer peritoneal cavity cancer |
|
Anti-Infective Agents Interferon Type I, Recombinant Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Gonadal Disorders Physiological Effects of Drugs Urogenital Neoplasms Ovarian Diseases Genital Diseases, Female Antibodies, Monoclonal Neoplasms by Site Therapeutic Uses Peritoneal Diseases Growth Inhibitors |
Angiogenesis Modulating Agents Endocrine Gland Neoplasms Immunoglobulins Interferon-alpha Ovarian Neoplasms Digestive System Neoplasms Growth Substances Mitosis Modulators Interferons Genital Neoplasms, Female Endocrine System Diseases Enzyme Inhibitors Antimitotic Agents Abdominal Neoplasms Angiogenesis Inhibitors |